Show simple item record

dc.contributor.authorLehrer, E. J.
dc.contributor.authorRuiz-Garcia, H.
dc.contributor.authorNehlsen, A. D.
dc.contributor.authorSindhu, K. K.
dc.contributor.authorEstrada, R. S.
dc.contributor.authorBorst, G. R.
dc.contributor.authorSheehan, J. P.
dc.contributor.authorQuinones-Hinojosa, A.
dc.contributor.authorTrifiletti, D. M.
dc.date.accessioned2022-03-09T13:35:22Z
dc.date.available2022-03-09T13:35:22Z
dc.date.issued2022en
dc.identifier.citationLehrer EJ, Ruiz-Garcia H, Nehlsen AD, Sindhu KK, Estrada RS, Borst GR, et al. Preoperative Stereotactic Radiosurgery for Glioblastoma [Internet]. Vol. 11, Biology. MDPI AG; 2022. p. 194.en
dc.identifier.pmid35205059en
dc.identifier.doi10.3390/biology11020194en
dc.identifier.urihttp://hdl.handle.net/10541/625121
dc.description.abstractGlioblastoma is a devastating primary brain tumor with a median overall survival of approximately 15 months despite the use of optimal modern therapy. While GBM has been studied for decades, modern therapies have allowed for a reduction in treatment-related toxicities, while the prognosis has largely been unchanged. Adjuvant stereotactic radiosurgery (SRS) was previously studied in GBM; however, the results were disappointing. SRS is a highly conformal radiation technique that permits the delivery of high doses of ionizing radiation in 1–5 sessions while largely sparing surrounding healthy tissues. Furthermore, studies have shown that the delivery of ablative doses of ionizing radiation within the central nervous system is associated with enhanced anti-tumor immunity. While SRS is commonly used in the definitive and adjuvant settings for other CNS malignancies, its role in the preoperative setting has become a topic of great interest due to the potential for reduced treatment volumes due to the treatment of an intact tumor, and a lower risk of nodular leptomeningeal disease and radiation necrosis. While early reports of SRS in the adjuvant setting for glioblastoma were disappointing, its role in the preoperative setting and its impact on the anti-tumor adaptive immune response is largely unknown. In this review, we provide an overview of GBM, discuss the potential role of preoperative SRS, and discuss the possible immunogenic effects of this therapy. en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.3390/biology11020194en
dc.titlePreoperative Stereotactic Radiosurgery for Glioblastomaen
dc.typeArticleen
dc.contributor.departmentDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL 32224, USA. Department of Neurological Surgery, Mayo Clinic, Jacksonville, FL 32224, USA. The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK. Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine & Health, The University of Manchester, 555 Wilmslow Road, Manchester M20 4GJ, UK. Department of Neurological Surgery, University of Virginia, Charlottesville, VA 22908, USA.en
dc.identifier.journalBiology (Basel)en
dc.description.noteen]
refterms.dateFOA2022-06-27T13:00:07Z


Files in this item

Thumbnail
Name:
Lehrer.pdf
Size:
11.80Mb
Format:
PDF
Description:
Identified with Open Access button

This item appears in the following Collection(s)

Show simple item record